このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC

A Study on the Safety and Efficacy of Atorvastatin in Combination With Axitinib and Toripalimab for Advanced Renal Cell Carcinoma Guided by Drug Sensitivity Testing Using Patient-Derived Tumor Cell Models

Given the significant challenge of drug resistance in patients with advanced renal cell carcinoma (RCC) despite standard treatment, this study aims to translate preclinical findings into clinical practice, preliminarily evaluating the safety, tolerability, and preliminary efficacy of atorvastatin calcium combined with targeted and immunotherapy in patients with advanced RCC. We hypothesize that for some patients with advanced RCC who do not respond well to targeted + immunotherapy, identifying potential beneficiaries based on their PTC susceptibility testing and combining atorvastatin with these treatments in real-world settings could be an effective susceptibility enhancement strategy, thereby further improving patient survival. This prospective clinical study aims to validate the safety and efficacy of this "organoid-guided precision combination therapy model."

調査の概要

詳細な説明

1. Study Objectives

1.1 Primary Objective: To evaluate the effectiveness of personalized treatment strategies guided by patient-derived tumor cell cluster (PTC) susceptibility testing in patients with advanced/metastatic renal cell carcinoma. The primary endpoint is objective response rate (ORR). Specifically, this study compares the in vitro drug sensitivity differences between two treatment regimens: "targeted therapy + immunotherapy" and "targeted therapy + immunotherapy + atorvastatin calcium tablets," by performing PTC culture and susceptibility testing on tumor tissue obtained from patient biopsies. This will guide subsequent clinical treatment decisions regarding the addition of oral atorvastatin calcium tablets to standard targeted therapy combined with immunotherapy.

1.2 Secondary Objectives:

  1. To evaluate the disease control rate, progression-free survival, overall survival, 12-month progression-free survival rate, and 12- and 24-month overall survival rates of atorvastatin combined with targeted and immunotherapy regimens in patients with advanced/metastatic renal cell carcinoma.
  2. Safety: Incidence of adverse events and serious adverse reactions.
  3. To evaluate health-related quality of life (HRQoL).

2. Study Design

2.1 Overall Design This is a single-center, prospective, non-randomized controlled, two-arm clinical trial of superiority. The study plans to enroll 20-40 patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). All subjects will receive targeted therapy plus immunotherapy. The addition of oral atorvastatin will be determined based on the drug sensitivity results of the patient-derived tumor cell cluster (PTC) model. Treatment will continue until any of the following occurs: disease progression, intolerable toxicity, the subject voluntarily requests to discontinue treatment or withdraw from the study, or other reasons determined by the investigator necessitate discontinuation of treatment and withdrawal from the study.

This study consists of three phases: screening, treatment (visit), and follow-up. All subjects must meet the inclusion and exclusion criteria. The screening period will not exceed 28 days. After passing the screening examination and evaluation, subjects will enter the treatment period. The treatment period consists of 21-day cycles, during which subjects must receive treatment and undergo regular visits as specified in the protocol.

Safety follow-up begins on day 30 (±7 days) from the start of the last study treatment, with participants required to undergo evaluation at the research center. Following the safety follow-up period, participants will enter a 2-year survival follow-up period, with follow-ups conducted at the end of every two treatment cycles. Follow-ups can be conducted via telephone or other effective methods, primarily collecting information on participant survival status and subsequent anti-tumor treatment. For participants without radiographic evidence of disease progression, imaging examinations will continue at the established efficacy assessment frequency until disease progression, death, loss to follow-up, withdrawal of informed consent, initiation of other anti-tumor treatments, or investigator termination of the study.

2.2 Study Endpoints

  1. Primary endpoint: Objective response rate (ORR);
  2. Secondary endpoints: Progression-free survival (PFS), overall survival (OS), disease control rate (DCR), 12-month progression-free survival rate (PFS rate), 12-month overall survival rate (OS rate), 24-month overall survival rate (OS rate), safety, and health-related quality of life (HRQoL).

2.3 Study Location and Duration

This study is planned to be conducted at a single center from April 2026 to April 2030, with the Cancer Hospital of the Chinese Academy of Medical Sciences as the main center. It is expected to enroll 20-40 patients with advanced or metastatic clear cell renal cell carcinoma.

2.4 Study Drugs

  1. Axitinib (Inritar)

    Dosage Form: Tablets

    Strength: 5mg/tablet

    Dosage: Oral

    The initial dose is 5mg twice daily, and the dose can be gradually adjusted according to patient tolerance.

  2. Toripalimab Injection (Tuoyi)

    Dosage Form: Injection

    Strength: 80mg/2ml

    Dosage: Intravenous Infusion

    Administer intravenously every 3 weeks at a dose of 240mg, continuously until disease progression or adverse reactions occur.

  3. Atorvastatin Calcium Tablets (Lipitor)

Dosage Form: Tablets

Strength: 10mg/tablet

Dosage: Oral

The initial dose is 10mg once daily, which can be gradually adjusted according to patient tolerance.

2.5 PTC Construction Procedure

This study used a patient-derived tumor cell cluster (PTC) model to assess drug sensitivity. The specific procedure included:

  1. Collecting tumor tissue samples from patients with advanced renal cell carcinoma and culturing them in vitro in the laboratory.
  2. Promoting the formation of tumor-like organoids by tumor cells under specific culture conditions, maintaining their biological characteristics in vitro.
  3. Performing drug sensitivity testing to evaluate two drug combinations: targeted therapy combined with immunotherapy (axitinib + toripalimab) or targeted therapy combined with immunotherapy and atorvastatin calcium tablets (axitinib + toripalimab + atorvastatin).
  4. Evaluating the inhibitory effect of different drug combinations on tumor cells in the PTC model by exposing them to different drug combinations, and deciding whether to provide combination therapy to patients based on the drug sensitivity results.

研究の種類

介入

入学 (推定)

40

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Chaoyang District
      • Beijing、Chaoyang District、中国、100021
        • Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing 101205
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Voluntarily agree to participate in the study and be willing and able to sign the informed consent form.
  2. Histologically confirmed clear cell renal cell carcinoma.
  3. Advanced renal cell carcinoma not suitable for curative surgery or radiotherapy, or metastatic renal cell carcinoma, AJCC stage IV.
  4. No prior systemic therapy for renal cell carcinoma, except for prior adjuvant or neoadjuvant therapy for completely resectable renal cell carcinoma, provided that the therapy did not include agents targeting VEGF or VEGFR and recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
  5. At least one measurable lesion according to RECIST version 1.1.
  6. Karnofsky Performance Status score ≥70.
  7. Estimated life expectancy of more than 3 months.
  8. Aged 18 to 75 years.
  9. Adequate major organ function and hematologic function, including:

    • Absolute neutrophil count ≥1500 cells/μL without granulocyte colony-stimulating factor support within 2 weeks before Cycle 1 Day 1.
    • Platelet count ≥80 × 10^9/L.
    • White blood cell count ≥2500/μL and ≤15000/μL without G-CSF support.
    • Lymphocyte count ≥500/μL.
    • Hemoglobin ≥9.0 g/dL, without erythropoietin dependence and without packed red blood cell transfusion within the previous 2 weeks.
    • ALT, AST, and alkaline phosphatase ≤3 × upper limit of normal; ≤5 × upper limit of normal is allowed for liver metastases. For participants with bone metastases, alkaline phosphatase ≤5 × upper limit of normal is allowed.
    • Total bilirubin ≤1.5 × upper limit of normal. Participants with known Gilbert syndrome may be enrolled if total bilirubin is ≤3 × upper limit of normal.
    • Serum albumin ≥2.8 g/dL.
    • Serum creatinine ≤2.0 × upper limit of normal or calculated creatinine clearance ≥30 mL/min.
    • Urine protein-to-creatinine ratio ≤1 mg/mg, equivalent to ≤113.2 mg/mmol.
  10. Female participants who are not postmenopausal or surgically sterile must agree to use two adequate contraceptive methods, including at least one method with an annual failure rate of less than 1%.
  11. Sexually active participants of reproductive potential and their partners must agree to use medically accepted contraceptive methods during the study and for 5 months after the last dose for female participants and 7 months after the last dose for male participants.
  12. Female participants of childbearing potential must not be pregnant at screen

Exclusion Criteria:

  1. Prior systemic therapy for renal cell carcinoma, unless the investigator can provide evidence that the participant was assigned to a placebo group.
  2. Known central nervous system metastases.
  3. Active malignancy within the past 24 months, except for renal cell carcinoma, definitively treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix or bladder. Participants with a history of localized low-risk prostate cancer may be eligible if they received curative treatment and have had no prostate-specific antigen recurrence within the past 5 years.
  4. Radiotherapy within 21 days before initiation of study treatment, except palliative radiotherapy for bone lesions completed at least 2 weeks before study treatment.
  5. Participation in another clinical study or receipt of an investigational drug within 4 weeks before initiation of study treatment.
  6. Receipt of a live vaccine within 30 days before planned initiation of study treatment.
  7. Proteinuria >1+ on urine dipstick. Participants with urine protein ≥1 g/24 hours on 24-hour urine collection are not eligible.
  8. Fasting total cholesterol >300 mg/dL, equivalent to 7.75 mmol/L, and/or fasting triglycerides >2.5 × upper limit of normal.
  9. Uncontrolled diabetes mellitus, defined as fasting blood glucose >1.5 × upper limit of normal. Participants may be enrolled after glucose-lowering treatment if adequately controlled.
  10. Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued bisphosphonate or denosumab therapy.
  11. QTc interval >480 ms.
  12. Inadequate recovery from toxicity or complications caused by major surgery before treatment initiation.
  13. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that may affect absorption of study drugs.
  14. Clinically significant hematuria, hematemesis, or hemoptysis of more than 0.5 teaspoon, approximately 2.5 mL, of red blood within 12 weeks before the first dose, or any other significant bleeding history.
  15. Significant cardiovascular impairment within 12 months before the first dose, including New York Heart Association class II or higher congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident, or hemodynamically unstable arrhythmia. Participants with left ventricular ejection fraction below the institutional lower limit of normal are also excluded.
  16. Active infection requiring systemic treatment.
  17. Positive human immunodeficiency virus test.
  18. Active hepatitis B or hepatitis C infection.
  19. Known history or evidence of interstitial lung disease.
  20. History of non-infectious pneumonitis requiring steroids or current pneumonitis.
  21. Diagnosis of immunodeficiency or receipt of chronic systemic steroid therapy or other immunosuppressive therapy within 7 days before the first dose. Physiologic corticosteroid doses up to prednisone 10 mg/day or equivalent are permitted.
  22. Active autoimmune disease requiring systemic treatment within the past 2 years, except psoriasis. Replacement therapy, such as thyroxine, insulin, or physiologic corticosteroid replacement therapy, is not considered systemic treatment.
  23. Breastfeeding or pregnancy at screening or baseline.
  24. Female participants of childbearing potential who do not agree to use highly effective contraception during the study and for 120 days after study termination.
  25. Male participants who have not undergone successful vasectomy and do not agree to use condoms with spermicide from the first dose until 120 days after the last dose, unless abstinent.
  26. Known intolerance to any study drug or any excipient.
  27. Prior allogeneic tissue or solid organ transplantation.
  28. Participants requiring analgesics must be on a stable analgesic regimen at study entry.
  29. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage once monthly or more frequently.
  30. Uncontrolled hypertension, defined as persistent systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg.
  31. Inability to swallow tablets or capsules.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Axitinib + Toripalimab
Participants will receive axitinib 5 mg orally twice daily and toripalimab 240 mg intravenously every 3 weeks as standard targeted therapy combined with immunotherapy.
Axitinib 5 mg orally twice daily.
Toripalimab 240 mg intravenously every 3 weeks.
実験的:Atorvastatin + Axitinib + Toripalimab
Participants will receive axitinib 5 mg orally twice daily, toripalimab 240 mg intravenously every 3 weeks, and atorvastatin calcium 10 mg orally once daily based on patient-derived tumor-like cell cluster drug sensitivity testing.
Axitinib 5 mg orally twice daily.
Toripalimab 240 mg intravenously every 3 weeks.
Atorvastatin calcium 10 mg orally once daily, administered based on patient-derived tumor-like cell cluster drug sensitivity testing.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate (ORR)
時間枠:From baseline until disease progression, death, withdrawal, or end of treatment, assessed up to 24 months.
ORR is defined as the proportion of participants who achieve complete response (CR) or partial response (PR) according to RECIST version 1.1.
From baseline until disease progression, death, withdrawal, or end of treatment, assessed up to 24 months.

二次結果の測定

結果測定
メジャーの説明
時間枠
Progression-Free Survival (PFS)
時間枠:From treatment initiation until disease progression or death, assessed up to 24 months.
PFS is defined as the time from treatment initiation to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
From treatment initiation until disease progression or death, assessed up to 24 months.
Overall Survival (OS)
時間枠:From treatment initiation until death from any cause, assessed up to 48 months.
OS is defined as the time from treatment initiation to death from any cause.
From treatment initiation until death from any cause, assessed up to 48 months.
Disease Control Rate (DCR)
時間枠:From baseline until disease progression, assessed up to 24 months.
DCR is defined as the proportion of participants who achieve complete response, partial response, or stable disease according to RECIST version 1.1.
From baseline until disease progression, assessed up to 24 months.
12-Month Progression-Free Survival Rate
時間枠:12 months after treatment initiation.
The proportion of participants who remain alive without disease progression at 12 months after treatment initiation.
12 months after treatment initiation.
12-Month Overall Survival Rate
時間枠:12 months after treatment initiation.
The proportion of participants who remain alive at 12 months after treatment initiation.
12 months after treatment initiation.
24-Month Overall Survival Rate
時間枠:24 months after treatment initiation.
The proportion of participants who remain alive at 24 months after treatment initiation.
24 months after treatment initiation.
Incidence of Adverse Events
時間枠:From treatment initiation to 30 days after the last dose of study treatment.
Safety will be assessed by the incidence and severity of adverse events and serious adverse events graded according to NCI-CTCAE version 5.0.
From treatment initiation to 30 days after the last dose of study treatment.
Health-Related Quality of Life (HRQoL)
時間枠:From baseline through treatment and follow-up, assessed up to 24 months.
HRQoL will be assessed using the EORTC QLQ-C30 questionnaire.
From baseline through treatment and follow-up, assessed up to 24 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年5月14日

一次修了 (推定)

2028年3月1日

研究の完了 (推定)

2030年4月1日

試験登録日

最初に提出

2026年6月1日

QC基準を満たした最初の提出物

2026年6月1日

最初の投稿 (実際)

2026年6月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月5日

QC基準を満たした最後の更新が送信されました

2026年6月1日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する